hypertriglyceridemia

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced new preclinical data demonstrating the delivery capabilities of its GalNAc conjugate technology in its hypercholesterolemia and hypertriglyceridemia programs.

The researchers identified an accumulation of rare variants in four genes identified by GWAS. They now plan to sequence more candidate genes using Sanger sequencing and, eventually, next-generation sequencing.

Using genome-wide association and targeted re-sequencing studies, a Canadian-led research team has uncovered common and rare genetic variants in four genes that are over-represented in individuals with extremely high blood triglyceride levels.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.